Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3128-3135

  Noordijk, Evert M ^a   Carde, Patrice ^b   Dupouy, Noëlle ^b   Hagenbeek, Anton ^b   Krol, Augustinus D G ^b   Kluin Nelemans, Johanna C ^b   Tirelli, Umberto ^b   Monconduit, Mathieu ^b   Thomas, José ^b   Eghbali, Houchingue ^b   Aleman, Berthe M P ^b   Bosq, Jacques ^b   Vovk, Marjeta ^b   Verschueren, Tom A M ^b   Pény, Anne Marie ^b   Girinsky, Théodore ^b   Raemaekers, John M M ^b   Henry Amar, Michel ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; EBVP PROTOCOL; MOPP ABV PROTOCOL; MOPP-ABV PROTOCOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DOXORUBICIN; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROCARBAZINE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 33745982566     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.2746     Document Type: Article

References (39)

1. Henry-Amar M, Somers R: Survival outcome after Hodgkin's disease: A report from the international data base on Hodgkin's disease. Semin Oncol 17:758-768, 1990
2. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003
3. Bergsagel DE, Alison RE, Bean HA, et al: Results of treating Hodgkin's disease without a policy of laparotomy staging. Cancer Treat Rep 66:717-731, 1982
4. Cosset JM, Henry-Amar M, Meerwaldt JH: Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience - EORTC Lymphoma Cooperative Group. Ann Oncol 2:77-82, 1991 (suppl 2)
5. Henry-Amar M, Hayat M, Meerwaldt JH, et al: Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols: EORTC Lymphoma Cooperative Group. Int J Radiat Oncol Biol Phys 19:1155-1157, 1990
6. Henry-Amar M: Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's Disease. Ann Oncol 3:117-128, 1992 (suppl 4)
7. Mauch PM, Kalish LA, Marcus KC, et al: Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 87:3625-3632, 1996
8. Ng AK, Bernardo MP, Weller E, et al: Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20:2101-2108, 2002
9. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12: 312-325, 1994
10. van Leeuwen FE, Klokman WJ, van 't Veer MB, et al: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18:487-497, 2000
11. Sieber M, Engert A, Diehl V: Treatment of Hodgkin's disease: Results and current concepts of the German Hodgkin's Lymphoma Study Group. Ann Oncol 11:81-85, 2000 (suppl 1)
12. Canellos GP: Current strategies for early Hodgkin's disease. Ann Oncol 7:91-93, 1996 (suppl 4)
13. Engert A, Schiller P, Josting A, et al: Involvedfield radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003
14. Tubiana M. Hayat M, Henry-Amar M, et al: Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease. Eur J Cancer 17:355-363, 1981
15. Tubiana M, Henry-Amar M, Carde P, et al: Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease: The EORTC Lymphoma Group controlled clinical trials - 1964-1987. Blood 73:47-56, 1989
16. Lee CK, Bloomfield CD, Goldman AI, et al: Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 46:2403-2409, 1980
17. Carde P, Burgers JM, Henry-Amar M, et al: Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors. J Clin Oncol 6:239-252, 1988
18. Gallez-Marchal D, Fayolle M, Henry-Amar M, et al: Radiation injuries of the gastrointestinal tract in Hodgkin's disease: The role of exploratory laparotomy and fractionation - A study of 19 cases observed in a series of 134 patients treated at the Institut Gustave Roussy from 1972 to 1982. Radiother Oncol 2:93-99, 1984
19. Rosenberg SA: Laparotomy and splenectomy in Hodgkin's disease: A reappraisal after twenty years. Scand J Haematol 34:289-292, 1985
20. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259, 1975
21. Hoerni B, Orgerie MB, Eghbali H, et al: New combination of epirubicine, bleomycin, vinblastine and prednisone (EBVP II) before radiotherapy in localized stages of Hodgkin's disease: Phase II trial in 50 patients. Bull Cancer 75:789-794, 1988
22. Hoerni B, Orgerie MB, Eghbali H, et al: Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radical radiotherapy in localized stages (I-IIIA) of Hodgkin's disease: Early results in 100 consecutive patients - Pierre-et-Marie-Curie Group. J Cancer Res Clin Oncol 117: 377-380, 1991
23. Zittoun R, Eghbali H, Audebert A, et al: The combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP) before radiotherapy in localized stages of Hodgkin's disease: Phase II trials. Bull Cancer 74:151-157, 1987
24. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
25. Zittoun R, Audebert A, Hoerni B, et al: Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 3:207-214, 1985
26. Klimo P, Connors JM: MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174-1182, 1985
27. Carde P, Hagenbeek A, Hayat M, et al: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group J Clin Oncol 11:2258-2272, 1993
28. Rothman KJ, Boice JD Jr: Epidemiologic Analysis With a Programmable Calculator. Boston, MA, Epidemiology Resources, 1982
29. Wartelle M, Kramar A, Jan P, et al: "PIGAS": An interactive statistical database management system, in Hammond R, McCarthy JL (eds): Proceedings of the Second International Workshop on Statistical Database Management. Springfield, VA, National Technical Information Service, Department of Commerce, 1983
30. Horning SJ, Hoppe RT, Hancock SL, et al: Vinblastine, bleomycin, and methotrexate: An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6:1822-1831, 1988
31. Canellos GP, Petroni GR, Barcos M, et al: Etoposide, vinblastine, and doxorubicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP - Cancer and Leukemia Group B. J Clin Oncol 13:2005-2011, 1995
32. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
33. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
34. Birdwell SH, Hancock SL, Varghese A, et al: Gastrointestinal cancer after treatment of Hodgkin's disease. Int J Radiat Oncol Biol Phys 37:67-73, 1997
35. Bhatia S, Robison LL, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745-751, 1996
36. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85:25-31, 1993
37. van Leeuwen FE, Klokman WJ, Stovall M, et al: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95:971-980, 2003
38. Yahalom J, Petrek JA, Biddinger PW, et al: Breast cancer in patients irradiated for Hodgkin's disease: A clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 10:1674-1681, 1992
39. Meyer RM, Gospodarowicz MK, Connors JM, et al: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005